MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Gilead Sciences Operating Cash Flow 2011-2026 | GILD
Annual Operating Cash Flow Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10 B | 10.8 B | 8.01 B | 9.07 B | 11.4 B | 8.17 B | 9.14 B | 8.4 B | 11.9 B | 17 B | 21.2 B | 12.8 B | 3.1 B | 3.2 B | 3.64 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 21.2 B | 3.1 B | 9.86 B |
Quarterly Operating Cash Flow Gilead Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 1.76 B | - | - | - | 2.22 B | - | - | - | 1.74 B | - | 6.5 B | 3.64 B | 1.84 B | - | 8.18 B | 4.93 B | 2.61 B | - | 6.25 B | 4 B | 1.44 B | - | 6.56 B | 3.92 B | 1.58 B | - | 6.06 B | 3.84 B | 2.27 B | - | 9.14 B | 6.45 B | 2.92 B | - | 13.5 B | 9.12 B | 4.13 B | - | 15.5 B | 11.4 B | 5.7 B | - | 9.8 B | 5.75 B | 1.57 B | - | 2.38 B | 1.63 B | 672 M | - | 2.49 B | 1.74 B | 453 M | - | 2.66 B | 1.76 B | 821 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.5 B | 453 M | 4.59 B |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.6 | 1.34 % | $ 8.66 B |  Australia |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.66 | - | $ 16.7 M |  USA |
 |
BioNTech SE
BNTX
|
890 M | $ 91.28 | - | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Burford Capital Limited
BUR
|
181 M | $ 4.48 | - | $ 736 M |  Britain |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
4.84 M | $ 1.85 | - | $ 353 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Coherus BioSciences
CHRS
|
-139 M | $ 1.67 | - | $ 196 M | USA |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-14.1 M | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-13.8 M | $ 2.32 | - | $ 1.03 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-64.5 M | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-37.9 M | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-27.2 M | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-378 M | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
-75.6 M | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-28.2 M | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
-21.7 M | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-121 M | $ 20.36 | - | $ 2.84 B | France |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Denali Therapeutics
DNLI
|
-348 M | $ 19.38 | - | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-5.7 M | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-10.6 M | $ 3.54 | - | $ 238 B | Britain |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Entera Bio Ltd.
ENTX
|
-10.4 M | $ 1.19 | - | $ 55.5 M | Israel |
 |
Equillium
EQ
|
-22.7 M | $ 2.01 | - | $ 115 M | USA |
 |
Allakos
ALLK
|
-116 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
-106 M | $ 1.19 | - | $ 141 M | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |